What are the key sales KPIs for the Contract Research Organization (CRO) industry in 2027?

👁 0 views📖 2,080 words⏱ 9 min read5/30/2026

Direct Answer

The nine KPIs that actually run a Contract Research Organization in 2027 are: Net New Business Awards ($B), Book-to-Bill Ratio, Contracted Backlog ($B), Backlog Conversion Rate (% per quarter), RFP Win Rate, Cancellation Rate, Gross Profit per Study, FSP Revenue Mix %, and Oncology + Rare-Disease Share of Pipeline %.

These nine numbers explain everything a sponsor, a CFO, or a sell-side analyst will ask about a CRO: are you winning new work faster than you are burning the old work, and is the work you are winning the kind that compounds.

TL;DR
— Net awards feed backlog, backlog feeds revenue, and the speed of conversion plus the cancellation rate decide whether the headline backlog is real cash or a vanity number. If book-to-bill drops below 1.10 for two quarters or trailing cancellations climb past 6%, the trajectory has already turned.
Track the nine KPIs weekly at the BU level, re-baseline therapeutic mix monthly, and treat FSP wins differently from full-service awards — that is the operating cadence IQVIA, ICON, and Medpace converged on after the 2024-2025 biotech funding reset.

Why Contract Research Organizations Work Differently

A CRO is not a professional services firm and it is not a SaaS business, even though Wall Street keeps trying to model it like one. Four mechanics make the category its own animal.

The backlog is the business. A CRO sells multi-year clinical trial contracts that convert to revenue over 3 to 5 years. IQVIA closed Q1 2026 with $34.2B in R&D Solutions contracted backlog, of which roughly $8.9B converts to revenue in the next twelve months. ICON ended FY2025 with $9.0B in full-year net business wins and a 1.09 book-to-bill.

Backlog is not pipeline — it is signed, scoped, and burning. Conversion velocity is the single biggest swing factor between guidance hits and guidance misses.

Cancellations are the silent killer. When biotech funding cracks, sponsors do not stop trials politely — they cancel scope, descope arms, or push start dates 6 months to the right. Medpace's Q4 2025 book-to-bill came in at 1.04 versus prior guidance of 1.15, with the company explicitly citing backlog cancellations at their highest level in over a year.

The stock lost roughly 30% in two sessions. A "well-behaved" cancellation rate is roughly 5% of backlog annually; anything north of 7% means the next two quarters of conversion are mismarked.

RFP win rate compounds slowly and decays fast. A typical large CRO bids on $15B-$25B of qualified RFP value per year and wins 18%-25% of it. A 200 basis-point shift in win rate is the difference between 1.05 and 1.20 book-to-bill. Win rate is driven by therapeutic-area depth, prior sponsor relationships, and FSP infrastructure — none of which can be conjured in a quarter.

When ICON absorbed PRA in 2021 and when Fortrea spun out of Labcorp in 2023, both companies spent 6+ quarters rebuilding bid-defense muscle.

Therapeutic mix dictates margin. A Phase III diabetes mega-trial runs at single-digit gross margin per study. A Phase II oncology basket trial or a rare-disease gene therapy program runs at 35%-50% gross margin because the protocol complexity, patient identification, and site network are scarce.

Every public CRO is racing to push oncology + rare disease past 50% of new awards because that mix is what supports the 18%-22% adjusted EBITDA margin the category is priced on.

The 9 KPIs, In Depth

1. Net New Business Awards ($B). Gross awards minus cancellations, the headline number every earnings call leads with. IQVIA reported $2.5B of Q1 2026 net new bookings; ICON posted $2.87B in Q4 2025; Medpace runs roughly $550M-$650M per quarter at scale.

Always split by full-service versus FSP — they carry different burn rates and different margins.

2. Book-to-Bill Ratio. Net awards divided by trailing-quarter revenue. The industry's accepted health band is 1.10-1.30; below 1.10 signals a coming revenue deceleration; above 1.30 is usually a one-quarter spike from a single mega-award.

ICON ran a 1.36 in Q4 2025, IQVIA a 1.18 in Q4 2025 and 1.04 in Q1 2026, Medpace 1.04 in Q4 2025.

3. Contracted Backlog ($B). The total dollar value of signed, unburned work. IQVIA's $34.2B is the industry's largest; ICON's backlog sits near $24B; Fortrea near $7.5B; Medpace closer to $3B at a different revenue scale. The number is meaningless without the next two KPIs attached.

4. Backlog Conversion Rate. Revenue recognized this quarter divided by opening backlog. The healthy band is 9.5%-11.0% per quarter for full-service work and 14%-18% for FSP. When conversion drops below 9% the explanation is either start-up delays, site activation problems, or unannounced cancellations working through the system.

5. RFP Win Rate. Awarded dollar value divided by qualified RFP dollar value bid. Industry median for the top 7 CROs is 20%-22%; best-in-class therapeutic specialists hit 28%-32% inside their core franchise.

Track by therapeutic area, by sponsor tier (top 20 pharma versus emerging biotech), and by award size band — a single metric hides the mix shift that actually matters.

6. Cancellation Rate. Cancelled or descoped backlog as a percent of opening backlog, annualized. Best-in-class operators sustain 4%-5%; the industry median is 5%-7%; anything above 7% in two consecutive quarters is what triggered the Medpace re-rating in February 2026.

Sponsor-funding mix (large pharma versus emerging biotech) is the single biggest predictor.

7. Gross Profit per Study. Lifetime gross profit divided by study count, segmented by phase and therapeutic area. A standard Phase III cardiovascular study runs 18%-22% gross margin; an oncology basket trial 35%-45%; a rare-disease gene therapy program can clear 50%. This is where mix shift shows up before it shows up in the P&L.

8. FSP Revenue Mix %. Functional Service Provision revenue as a share of total. The category grew from roughly 18% of large-CRO revenue in 2020 to an estimated 30%-35% in 2026, with IQVIA, ICON, and Parexel running dedicated FSP business units.

FSP carries lower revenue per FTE but higher conversion velocity and lower cancellation risk — different unit economics, modeled separately.

9. Oncology + Rare-Disease Share of Pipeline %. Net new awards in oncology and rare disease as a share of total awards. The industry has moved from roughly 38% in 2022 to north of 52% in 2026.

Medpace runs above 40% oncology specifically; ICON's combined oncology + rare disease is roughly 55% of awards. This is the single best leading indicator of forward gross margin.

flowchart TD A[Qualified RFP Pipeline] --> B{Bid Defense} B -->|Win 20-25%| C[Gross Award] B -->|Lose| D[Lost RFP - Feedback Loop] C --> E{Cancellation Filter} E -->|Net 93-95%| F[Net New Award] E -->|Cancel 5-7%| G[Backlog Adjustment] F --> H[Add to Contracted Backlog] H --> I{Conversion 9-11% per Quarter} I --> J[Quarterly Revenue] J --> K{Therapeutic Mix} K -->|Onco / Rare 50%+| L[High Gross Margin 35-45%] K -->|Standard Therapeutic| M[Mid Gross Margin 18-22%] L --> N[Adjusted EBITDA 18-22%] M --> N N --> O[Reinvest in FSP + AI + Site Network] O --> A

Real Operators

IQVIA is the scale benchmark — $34.2B backlog, $2.5B Q1 2026 net awards, and a Connected Intelligence platform that bundles real-world data into bid defense. ICON (post-PRA Health Sciences merger, 2021) is the closest peer — $9.0B in 2025 net wins, 1.09 book-to-bill, and the largest FSP franchise in the category.

Labcorp Drug Development spun out as Fortrea in mid-2023 under CEO Tom Pike, carrying roughly 19,000 employees and the Covance legacy. Syneos Health was taken private by Elliott in 2023 and is rebuilding under new leadership. Parexel (PE-owned by EQT and Goldman) runs ~21,000 employees and an estimated $3.8B in 2025 revenue, with a strong mid-tier biotech franchise.

Charles River Laboratories dominates preclinical and early development. PPD is now embedded inside Thermo Fisher's Clinical Research Group after the 2021 acquisition. Medpace is the small-mid-biotech specialist that took the Q4 2025 cancellation-rate hit and triggered the broader CRO re-rating in early 2026.

Worldwide Clinical Trials and Premier Research round out the rare-disease and Phase II specialist tier.

Failure Modes

The four ways CROs blow themselves up. (1) Backlog vanity — booking gross awards as backlog without rigorous cancellation reserve, then taking the write-down four quarters later when conversion misses; this is what eventually broke the pre-2020 valuation premium for the category.

(2) Sponsor concentration — when emerging biotech is more than 35% of net awards, a funding cycle turn (like 2022-2024) can cancel 8-10% of backlog inside two quarters. (3) FSP-cannibalization blindness — letting full-service revenue migrate to lower-revenue-per-FTE FSP contracts without re-baselining the cost model; ICON and IQVIA both rebuilt FP&A around this in 2024.

(4) Therapeutic-area drift — chasing whichever indication is hot this year (GLP-1, then ADCs, then radiopharmaceuticals) without building durable site networks; the win rate decays inside 18 months when the network is rented rather than owned.

Reporting Cadence

Daily: RFP issuances received, bid defenses scheduled, site activations, screen-failure escalations. Weekly: net new awards run-rate, cancellation queue, top-10 sponsor pipeline health, FSP versus full-service mix of new awards. Monthly: backlog conversion by therapeutic area, gross profit per study by phase, RFP win rate by sponsor tier, FSP utilization.

Quarterly: full P&L, book-to-bill by BU, backlog roll-forward with cancellation reserve true-up, therapeutic mix shift for the earnings call.

flowchart TD A[Daily Operating Telemetry] --> B[RFPs In + Bid Defenses + Site Activations] B --> C[Weekly BU Review] C --> D[Net Awards Run-Rate + Cancellation Queue + FSP Mix] D --> E[Monthly Business Review] E --> F[Conversion by TA + GP per Study + Win Rate by Sponsor] F --> G[Quarterly Earnings + Board] G --> H[Backlog Roll-Forward + Cancellation True-Up + TA Mix] H --> I[Re-Forecast Revenue + Reset Bid-Defense Priorities] I --> A

30/60/90 Day Plan

Days 1-30: instrument the nine KPIs by business unit. Reconcile backlog across CRM, contracts, and finance — the three systems will not match, and the gap is the first finding. Establish baseline RFP win rate by therapeutic area and sponsor tier; baseline cancellation rate trailing 8 quarters.

Pull ACRO and CenterWatch peer benchmarks for context.

Days 31-60: ship the backlog-conversion dashboard wired to study-level burn schedules on one side and start-up milestone telemetry on the other. Build the FSP-versus-full-service unit economics model; if FSP is more than 25% of revenue, FP&A needs a separate cost-to-serve view.

Brief the bid-defense leadership on the bottom-quartile win-rate therapeutic areas and decide what to bid less of.

Days 61-90: run the first quarterly cancellation-reserve true-up against the new model. Re-baseline oncology + rare-disease share of new awards and set the 12-month target. Present the new operating model to the CFO with monthly checkpoints and a single-page board exhibit covering book-to-bill, backlog, conversion, cancellation, and therapeutic mix.

FAQ

Is book-to-bill or backlog the better health metric? Book-to-bill, on a trailing-twelve-month basis. A single quarter swings on one mega-award. The TTM number smooths the noise and is what every sell-side analyst models against. Backlog without conversion velocity attached is decorative.

How should we treat FSP awards versus full-service? Track them as separate revenue streams with separate book-to-bill, conversion, and gross-margin targets. FSP converts faster (14%-18% per quarter), cancels less, and earns lower revenue per FTE. Blending the two hides the mix shift that the analyst community has been pricing into the multiple since 2024.

What cancellation rate is the red flag? Anything north of 7% of opening backlog annualized for two consecutive quarters. Medpace's February 2026 disclosure of elevated cancellations is the textbook case — the stock re-rated within 48 hours of the print despite the company arguing the cancellations were sponsor-specific.

Why does oncology + rare-disease share matter so much? Because gross margin per study in those indications runs 2x to 2.5x a standard Phase III cardiovascular or metabolic trial. The mix shift is the single biggest lever on forward EBITDA margin, and every major CRO has been re-engineering bid defense around it since the 2023 funding reset.

Sources

ACRO — Association of Clinical Research Organizations, 2026 Industry Outlook
CenterWatch — CRO Industry Benchmarks and Sponsor Surveys
Tufts Center for the Study of Drug Development — Impact Reports on CRO Outsourcing
ClinicalTrials.gov — Trial Registry and Sponsor / CRO Disclosure Data
BioPharma Catalyst — Clinical Trial and CRO Award Tracking
IQVIA Holdings Inc. — Form 10-K (FY2025) and Q1 2026 8-K Earnings Release
ICON plc — Form 20-F and Q4 2025 / FY2025 6-K Earnings Release
Fortrea Holdings Inc. — Form 10-K (FY2025) and Investor Presentations
Medpace Holdings Inc. — Form 10-K (FY2025) and Q4 2025 Earnings Release
ISR Reports — Phase I CRO Benchmarking, 17th Edition

Keep reading

Download:

### Direct Answer

The nine KPIs that actually run a Contract Research Organization in 2027 are: **Net New Business Awards ($B)**, **Book-to-Bill Ratio**, **Contracted Backlog ($B)**, **Backlog Conversion Rate (% per quarter)**, **RFP Win Rate**, **Cancellation Rate**, **Gross Profit per Study**, **FSP Revenue Mix %**, and **Oncology + Rare-Disease Share of Pipeline %**. These nine numbers explain everything a sponsor, a CFO, or a sell-side analyst will ask about a CRO: are you winning new work faster than you are burning the old work, and is the work you are winning the kind that compounds.

> **TL;DR** — Net awards feed backlog, backlog feeds revenue, and the speed of conversion plus the cancellation rate decide whether the headline backlog is real cash or a vanity number. If book-to-bill drops below 1.10 for two quarters or trailing cancellations climb past 6%, the trajectory has already turned. Track the nine KPIs weekly at the BU level, re-baseline therapeutic mix monthly, and treat FSP wins differently from full-service awards — that is the operating cadence IQVIA, ICON, and Medpace converged on after the 2024-2025 biotech funding reset.

## Why Contract Research Organizations Work Differently

A CRO is not a professional services firm and it is not a SaaS business, even though Wall Street keeps trying to model it like one. Four mechanics make the category its own animal.

**The backlog is the business.** A CRO sells multi-year clinical trial contracts that convert to revenue over 3 to 5 years. IQVIA closed Q1 2026 with **$34.2B in R&D Solutions contracted backlog**, of which roughly **$8.9B** converts to revenue in the next twelve months. ICON ended FY2025 with **$9.0B in full-year net business wins** and a **1.09 book-to-bill**. Backlog is not pipeline — it is signed, scoped, and burning. Conversion velocity is the single biggest swing factor between guidance hits and guidance misses.

**Cancellations are the silent killer.** When biotech funding cracks, sponsors do not stop trials politely — they cancel scope, descope arms, or push start dates 6 months to the right. Medpace's **Q4 2025 book-to-bill came in at 1.04** versus prior guidance of **1.15**, with the company explicitly citing **backlog cancellations at their highest level in over a year**. The stock lost roughly 30% in two sessions. A "well-behaved" cancellation rate is roughly **5% of backlog annually**; anything north of 7% means the next two quarters of conversion are mismarked.

**RFP win rate compounds slowly and decays fast.** A typical large CRO bids on **$15B-$25B of qualified RFP value per year** and wins **18%-25%** of it. A 200 basis-point shift in win rate is the difference between 1.05 and 1.20 book-to-bill. Win rate is driven by therapeutic-area depth, prior sponsor relationships, and FSP infrastructure — none of which can be conjured in a quarter. When ICON absorbed PRA in 2021 and when Fortrea spun out of Labcorp in 2023, both companies spent 6+ quarters rebuilding bid-defense muscle.

**Therapeutic mix dictates margin.** A Phase III diabetes mega-trial runs at single-digit gross margin per study. A Phase II oncology basket trial or a rare-disease gene therapy program runs at **35%-50% gross margin** because the protocol complexity, patient identification, and site network are scarce. Every public CRO is racing to push **oncology + rare disease past 50% of new awards** because that mix is what supports the **18%-22% adjusted EBITDA margin** the category is priced on.

## The 9 KPIs, In Depth

**1. Net New Business Awards ($B).** Gross awards minus cancellations, the headline number every earnings call leads with. IQVIA reported **$2.5B of Q1 2026 net new bookings**; ICON posted **$2.87B in Q4 2025**; Medpace runs roughly **$550M-$650M per quarter** at scale. Always split by full-service versus FSP — they carry different burn rates and different margins.

**2. Book-to-Bill Ratio.** Net awards divided by trailing-quarter revenue. The industry's accepted health band is **1.10-1.30**; below **1.10** signals a coming revenue deceleration; above **1.30** is usually a one-quarter spike from a single mega-award. ICON ran a **1.36 in Q4 2025**, IQVIA a **1.18 in Q4 2025** and **1.04 in Q1 2026**, Medpace **1.04 in Q4 2025**.

**3. Contracted Backlog ($B).** The total dollar value of signed, unburned work. IQVIA's **$34.2B** is the industry's largest; ICON's backlog sits near **$24B**; Fortrea near **$7.5B**; Medpace closer to **$3B** at a different revenue scale. The number is meaningless without the next two KPIs attached.

**4. Backlog Conversion Rate.** Revenue recognized this quarter divided by opening backlog. The healthy band is **9.5%-11.0% per quarter** for full-service work and **14%-18%** for FSP. When conversion drops below 9% the explanation is either start-up delays, site activation problems, or unannounced cancellations working through the system.

**5. RFP Win Rate.** Awarded dollar value divided by qualified RFP dollar value bid. Industry median for the top 7 CROs is **20%-22%**; best-in-class therapeutic specialists hit **28%-32%** inside their core franchise. Track by therapeutic area, by sponsor tier (top 20 pharma versus emerging biotech), and by award size band — a single metric hides the mix shift that actually matters.

**6. Cancellation Rate.** Cancelled or descoped backlog as a percent of opening backlog, annualized. Best-in-class operators sustain **4%-5%**; the industry median is **5%-7%**; anything **above 7%** in two consecutive quarters is what triggered the Medpace re-rating in February 2026. Sponsor-funding mix (large pharma versus emerging biotech) is the single biggest predictor.

**7. Gross Profit per Study.** Lifetime gross profit divided by study count, segmented by phase and therapeutic area. A standard Phase III cardiovascular study runs **18%-22% gross margin**; an oncology basket trial **35%-45%**; a rare-disease gene therapy program can clear **50%**. This is where mix shift shows up before it shows up in the P&L.

**8. FSP Revenue Mix %.** Functional Service Provision revenue as a share of total. The category grew from roughly **18% of large-CRO revenue in 2020** to an estimated **30%-35% in 2026**, with IQVIA, ICON, and Parexel running dedicated FSP business units. FSP carries lower revenue per FTE but **higher conversion velocity** and lower cancellation risk — different unit economics, modeled separately.

**9. Oncology + Rare-Disease Share of Pipeline %.** Net new awards in oncology and rare disease as a share of total awards. The industry has moved from roughly **38% in 2022 to north of 52% in 2026**. Medpace runs above **40% oncology specifically**; ICON's combined oncology + rare disease is roughly **55% of awards**. This is the single best leading indicator of forward gross margin.

```mermaid
flowchart TD
    A[Qualified RFP Pipeline] --> B{Bid Defense}
    B -->|Win 20-25%| C[Gross Award]
    B -->|Lose| D[Lost RFP - Feedback Loop]
    C --> E{Cancellation Filter}
    E -->|Net 93-95%| F[Net New Award]
    E -->|Cancel 5-7%| G[Backlog Adjustment]
    F --> H[Add to Contracted Backlog]
    H --> I{Conversion 9-11% per Quarter}
    I --> J[Quarterly Revenue]
    J --> K{Therapeutic Mix}
    K -->|Onco / Rare 50%+| L[High Gross Margin 35-45%]
    K -->|Standard Therapeutic| M[Mid Gross Margin 18-22%]
    L --> N[Adjusted EBITDA 18-22%]
    M --> N
    N --> O[Reinvest in FSP + AI + Site Network]
    O --> A
```

## Real Operators

**IQVIA** is the scale benchmark — **$34.2B backlog**, **$2.5B Q1 2026 net awards**, and a Connected Intelligence platform that bundles real-world data into bid defense. **ICON** (post-PRA Health Sciences merger, 2021) is the closest peer — **$9.0B in 2025 net wins**, **1.09 book-to-bill**, and the largest FSP franchise in the category. **Labcorp Drug Development** spun out as **Fortrea** in mid-2023 under CEO Tom Pike, carrying roughly **19,000 employees** and the Covance legacy. **Syneos Health** was taken private by Elliott in 2023 and is rebuilding under new leadership. **Parexel** (PE-owned by EQT and Goldman) runs **~21,000 employees** and an estimated **$3.8B in 2025 revenue**, with a strong mid-tier biotech franchise. **Charles River Laboratories** dominates preclinical and early development. **PPD** is now embedded inside **Thermo Fisher's Clinical Research Group** after the 2021 acquisition. **Medpace** is the small-mid-biotech specialist that took the **Q4 2025 cancellation-rate hit** and triggered the broader CRO re-rating in early 2026. **Worldwide Clinical Trials** and **Premier Research** round out the rare-disease and Phase II specialist tier.

## Failure Modes

The four ways CROs blow themselves up. **(1) Backlog vanity** — booking gross awards as backlog without rigorous cancellation reserve, then taking the write-down four quarters later when conversion misses; this is what eventually broke the pre-2020 valuation premium for the category. **(2) Sponsor concentration** — when emerging biotech is more than 35% of net awards, a funding cycle turn (like 2022-2024) can cancel 8-10% of backlog inside two quarters. **(3) FSP-cannibalization blindness** — letting full-service revenue migrate to lower-revenue-per-FTE FSP contracts without re-baselining the cost model; ICON and IQVIA both rebuilt FP&A around this in 2024. **(4) Therapeutic-area drift** — chasing whichever indication is hot this year (GLP-1, then ADCs, then radiopharmaceuticals) without building durable site networks; the win rate decays inside 18 months when the network is rented rather than owned.

## Reporting Cadence

**Daily:** RFP issuances received, bid defenses scheduled, site activations, screen-failure escalations. **Weekly:** net new awards run-rate, cancellation queue, top-10 sponsor pipeline health, FSP versus full-service mix of new awards. **Monthly:** backlog conversion by therapeutic area, gross profit per study by phase, RFP win rate by sponsor tier, FSP utilization. **Quarterly:** full P&L, book-to-bill by BU, backlog roll-forward with cancellation reserve true-up, therapeutic mix shift for the earnings call.

```mermaid
flowchart TD
    A[Daily Operating Telemetry] --> B[RFPs In + Bid Defenses + Site Activations]
    B --> C[Weekly BU Review]
    C --> D[Net Awards Run-Rate + Cancellation Queue + FSP Mix]
    D --> E[Monthly Business Review]
    E --> F[Conversion by TA + GP per Study + Win Rate by Sponsor]
    F --> G[Quarterly Earnings + Board]
    G --> H[Backlog Roll-Forward + Cancellation True-Up + TA Mix]
    H --> I[Re-Forecast Revenue + Reset Bid-Defense Priorities]
    I --> A
```

## 30/60/90 Day Plan

**Days 1-30:** instrument the nine KPIs by business unit. Reconcile backlog across CRM, contracts, and finance — the three systems will not match, and the gap is the first finding. Establish baseline RFP win rate by therapeutic area and sponsor tier; baseline cancellation rate trailing 8 quarters. Pull ACRO and CenterWatch peer benchmarks for context.

**Days 31-60:** ship the backlog-conversion dashboard wired to study-level burn schedules on one side and start-up milestone telemetry on the other. Build the FSP-versus-full-service unit economics model; if FSP is more than 25% of revenue, FP&A needs a separate cost-to-serve view. Brief the bid-defense leadership on the bottom-quartile win-rate therapeutic areas and decide what to bid less of.

**Days 61-90:** run the first quarterly cancellation-reserve true-up against the new model. Re-baseline oncology + rare-disease share of new awards and set the 12-month target. Present the new operating model to the CFO with monthly checkpoints and a single-page board exhibit covering book-to-bill, backlog, conversion, cancellation, and therapeutic mix.

## FAQ

**Is book-to-bill or backlog the better health metric?** Book-to-bill, on a trailing-twelve-month basis. A single quarter swings on one mega-award. The TTM number smooths the noise and is what every sell-side analyst models against. Backlog without conversion velocity attached is decorative.

**How should we treat FSP awards versus full-service?** Track them as separate revenue streams with separate book-to-bill, conversion, and gross-margin targets. FSP converts faster (14%-18% per quarter), cancels less, and earns lower revenue per FTE. Blending the two hides the mix shift that the analyst community has been pricing into the multiple since 2024.

**What cancellation rate is the red flag?** Anything north of **7% of opening backlog annualized for two consecutive quarters**. Medpace's February 2026 disclosure of elevated cancellations is the textbook case — the stock re-rated within 48 hours of the print despite the company arguing the cancellations were sponsor-specific.

**Why does oncology + rare-disease share matter so much?** Because gross margin per study in those indications runs **2x to 2.5x** a standard Phase III cardiovascular or metabolic trial. The mix shift is the single biggest lever on forward EBITDA margin, and every major CRO has been re-engineering bid defense around it since the 2023 funding reset.

## Sources

- ACRO — Association of Clinical Research Organizations, 2026 Industry Outlook
- CenterWatch — CRO Industry Benchmarks and Sponsor Surveys
- Tufts Center for the Study of Drug Development — Impact Reports on CRO Outsourcing
- ClinicalTrials.gov — Trial Registry and Sponsor / CRO Disclosure Data
- BioPharma Catalyst — Clinical Trial and CRO Award Tracking
- IQVIA Holdings Inc. — Form 10-K (FY2025) and Q1 2026 8-K Earnings Release
- ICON plc — Form 20-F and Q4 2025 / FY2025 6-K Earnings Release
- Fortrea Holdings Inc. — Form 10-K (FY2025) and Investor Presentations
- Medpace Holdings Inc. — Form 10-K (FY2025) and Q4 2025 Earnings Release
- ISR Reports — Phase I CRO Benchmarking, 17th Edition

Was this helpful?

Related in the library